Phase 3 N=720 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 289; 259 Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,224 Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
Chronic Obstructive Pulmonary Disease
Primary: Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period. — 0.94; 1.07…
Phase 2 N=50 TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
HIV Infections · Acquired Immunodeficiency Syndrome
Primary: Pharmacokinetic Results of Atazanavir (ATV): Treatment A: ATV/Low-Dose Ritonavir (Rtv) 300/100 mg (Results for C0h, Cmin, and Cmax) — 1339; 845.7; 1104; 758.6 ng/ml
N/A N=160 Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU
Diabetes or With New Hyperglycemia
Primary: Mean Blood Glucose (BG) in mg/dl Among Glucommander Group Compared to Standard Insulin Infusion — 103.3; 117.3 mg/dl
Phase 2 N=61 A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Percent Change in Total Sperm Count Per Ejaculate — 3.62; -12.22 Percent change
Phase 2 N=120 Provoked Craving Relief Study by NRT
Smoking Cessation
Primary: Mean Change From Baseline in Nicotine Craving Score on a VAS — -11.3; -1.7; -4.6; -28.2 Score on a scale
Phase 4 N=49 Kidney Damage in Patients With Normal eGFR
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media. — -14.84; -17.71; -9.98; -2.37 ng/mL
N/A N=49 A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation
Lung Cancer · Head and Neck Cancer
Primary: [F-18]FLT PET Scan for Early Assessment of Tumor Response to Radiation or Chemoradiotherapy Compared to [F-18] FDG PET Scan
Phase 3 N=85 Oral Aripiprazole Open-Label Rollover Study
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths — 61; 11; 7; 1 Participants
N/A N=88 Chronic Total Occlusion Crossing With the Wildcat Catheter
Peripheral Arterial Disease
Primary: Major Adverse Events — 4 participants
Phase 4 N=924 Clarithromycin Resistant Tailored Therapy
Peptic Ulcer · Helicobacter Pylori Infection
Primary: Helicobacter Pylori Eradication Rate — 75.9; 91.2; 79.1 percentage of participants
Phase 2 N=35 Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation
Neurotic Excoriation · Pathologic Skin Picking · Psychogenic Excoriation
Primary: The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) Will be the Primary Outcome Measure — 15.25; 16.13 units on a scale
Phase 2 N=22 Metabolic Effects of Paricalcitol
Chronic Kidney Disease
Primary: Glucose Area Under the Curve (AUC) — 20817; 21139 mg*min/dL
Phase 3 N=22 Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
Diabetes Mellitus · Chronic Kidney Disease · Diabetic Kidney Disease
Primary: Change in Urine Albumin Excretion — -21; -5 percent difference
Phase 4 N=52 Influence of Escitalopram on Fear Conditioning
Fear Conditioning
Primary: Physiological Reactivity as Measured by Square-root Transformed Skin Conductance Conditioned Response in Early Extinction Trials 1 to 4 — 0.745; 0.853; 0.799; 0.717…